Although BRAF V600E‐positive GBMs account for only 3% of whole cases, the BRAF‐FOSL1 axis appears to be potentially relevant, given that BRAF is the upstream signaling molecule of FOSL1 in colon cancer and that both molecules share the MAPK signaling pathway [33, 44]. Here, BRAF is linked to malignant colon neoplasm.